EE133 COST-EFFECTIVENESS ANALYSIS OF PAZOPANIB VERSUS SUNITINIB FOR THE TREATMENT OF FIRST-LINE ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA IN CHINA: USING PARTITIONED SURVIVAL MODEL AND MARKOV MODEL
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.383
https://www.valueinhealthjournal.com/article/S1098-3015(22)00584-8/fulltext
Title :
EE133 COST-EFFECTIVENESS ANALYSIS OF PAZOPANIB VERSUS SUNITINIB FOR THE TREATMENT OF FIRST-LINE ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA IN CHINA: USING PARTITIONED SURVIVAL MODEL AND MARKOV MODEL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00584-8&doi=10.1016/j.jval.2022.04.383
First page :
Section Title :
Open access? :
No
Section Order :
10336